Veradermics (MANE) Research & Development (2025 - 2026)

Veradermics (MANE) posted Research & Development of $20.9 million for Q1 2026, up 82.8% on a QoQ basis from $11.4 million in Q1 2025, and up 82.8% year-over-year from $11.4 million in Q1 2025.

Veradermics (MANE) Research & Development (2025 - 2026) Analysis & Trends

Veradermics' Research & Development history runs 2 years deep, the most recent figure standing at $20.9 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -17.94 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 541.22 Mn
4 NuCana 279.75 Bn 279.75 Bn - -2.31 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 961.60 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 1.54 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 15.66 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 1.37 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 343.97 Mn
10 Veradermics 2.63 Bn 2.63 Bn - 20.93 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 20.93 Mn
Mar 31, 2025 11.45 Mn